Form 8-K - Current report:
SEC Accession No. 0001193125-24-000991
Filing Date
2024-01-03
Accepted
2024-01-03 06:37:51
Documents
15
Period of Report
2024-01-03
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d586587d8k.htm   iXBRL 8-K 46551
2 EX-99.1 d586587dex991.htm EX-99.1 39144
6 GRAPHIC g586587g0103081534782.jpg GRAPHIC 631
7 GRAPHIC g586587g0103082505228.jpg GRAPHIC 2809
  Complete submission text file 0001193125-24-000991.txt   229096

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dyn-20240103.xsd EX-101.SCH 2847
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE dyn-20240103_lab.xml EX-101.LAB 17978
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dyn-20240103_pre.xml EX-101.PRE 11257
9 EXTRACTED XBRL INSTANCE DOCUMENT d586587d8k_htm.xml XML 3341
Mailing Address 1560 TRAPELO ROAD WALTHAM MA 02451
Business Address 1560 TRAPELO ROAD WALTHAM MA 02451 (781) 786-8230
Dyne Therapeutics, Inc. (Filer) CIK: 0001818794 (see all company filings)

EIN.: 364883909 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39509 | Film No.: 24504316
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)